PATENT CLAIM ANALYSIS

Application Number: 15939218
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "428000"]

Abstract:
The disclosure provides methods for treating estrogen receptor positive (ER + ) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER +  cancers.

Claim (Index 20):
The method of  claim 18 , wherein the patient has previously been treated with one or two prior lines of endocrine therapy, and wherein at least one of the prior lines of endocrine therapy is treatment with an aromatase inhibitor.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 90.0
- Lexical Diversity: 1.28
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14645578', '14753397', '14717069', '15589391', '16475980']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7937132751527014
- 35 USC 102 Novelty (BERT): 0.5258467935778026
- Combined Prediction Score: 0.7669266269952115
- Mean Citation Score: 320.457534
- Max Citation Score: 345.9269700000001
- Similarity Product: 238.66987623180992

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test